WebApr 18, 2024 · This phase 1/2 study assessed parsaclisib (INCB050465), a next-generation, potent, and highly selective phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor, in patients … Webparsaclisinib;placebo: 3: An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type …
Parsabiv (Etelcalcetide for Injection): Uses, Dosage, …
WebDr. Eunice Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center. Dr. Wang joined the Roswell Park faculty in 2003 and was appointed to the Leukemia Service of the Department of Medicine. She earned her medical degree from the Keck School of Medicine, University of Southern California and completed residency ... WebMay 3, 2024 · Drug: parsaclisinib; Drug: placebo; Phase 3: Detailed Description. Prospective participants must have primary wAIHA as well as other protocol-defined … mongodb search in a list
2024年Q1 失败临床研究TOP28 单抗 单药 安慰剂 top 治疗组 肿 …
Webparsaclisinib; placebo; Los Angeles, California +52 more; May 2, 2024. Warm Autoimmune Hemolytic Anemia (wAIHA) Trial in Worldwide (Isatuximab SAR650984) Recruiting. Warm Autoimmune Hemolytic Anemia (wAIHA) Isatuximab SAR650984; Los Angeles, California +8 more; Mar 16, 2024. Clincosm, Inc. (888) 254-6267 [email protected]. WebOpinion/decision on a Paediatric investigation plan (PIP): Parsaclisib (as hydrochloride), decision type: , therapeutic area: , PIP number: P/0085/2024 Opinion/decision on a Paediatr #Europe #FDA #MedicalDevices #Medicines mongodb search in array of strings